Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
44.22
+0.75 (1.73%)
Dec 20, 2024, 4:00 PM EST - Market closed
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for RARE stock have an average target of 88.43, with a low estimate of 46 and a high estimate of 127. The average target predicts an increase of 99.98% from the current stock price of 44.22.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RARE stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 6 | 6 |
| Buy | 8 | 9 | 9 | 9 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $75 → $88 | Buy | Maintains | $75 → $88 | +99.00% | Dec 20, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $105 → $102 | Buy | Maintains | $105 → $102 | +130.66% | Nov 21, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $121 | Strong Buy | Maintains | $121 | +173.63% | Nov 12, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $109 → $121 | Strong Buy | Maintains | $109 → $121 | +173.63% | Nov 6, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $77 | Buy | Reiterates | $77 | +74.13% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
553.06M
from 434.25M
Increased by 27.36%
Revenue Next Year
655.96M
from 553.06M
Increased by 18.61%
EPS This Year
-6.28
from -8.25
EPS Next Year
-5.19
from -6.28
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 581.4M | 826.4M | 1.2B | |||
| Avg | 553.1M | 656.0M | 888.9M | |||
| Low | 522.8M | 575.3M | 682.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 33.9% | 49.4% | 78.5% | |||
| Avg | 27.4% | 18.6% | 35.5% | |||
| Low | 20.4% | 4.0% | 4.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -4.74 | -3.83 | -0.66 | |||
| Avg | -6.28 | -5.19 | -3.12 | |||
| Low | -6.56 | -6.03 | -4.87 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.